![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
HBV RNAi inhibitor RG6346 in Phase 1b-2a trial
was safe, well-tolerated, and resulted in substantial
and durable reductions in serum HBsAg levels
|
|
|
AASLD 2020 Nov 11-16
Late Breaker
Prof. Man-Fung Yuen, M.D., Ph.D., D.Sc. Queen Mary Hospital, The University of Hong Kong, Hong Kong
![1120201](../images/112020/112020-10/1120201.gif)
![1120202](../images/112020/112020-10/1120202.gif)
![1120203](../images/112020/112020-10/1120203.gif)
![1120204](../images/112020/112020-10/1120204.gif)
![1120205](../images/112020/112020-10/1120205.gif)
![1120206](../images/112020/112020-10/1120206.gif)
![1120207](../images/112020/112020-10/1120207.gif)
![1120208](../images/112020/112020-10/1120208.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|